Martin C. Tammemägi

Advisor at Nucleix

Tammemägi has MSc and PhD degrees in Epidemiology from the University of Toronto. He served as co-investigator in the US NIH NCI sponsored National Lung Screening Trial. Currently, he is Professor of Epidemiology in the Department of Health Sciences at Brock University in Canada and is Scientific Lead on Cancer Care Ontario’s Lung Cancer Screening Pilot for People at High Risk. His research has a focus on lung cancer screening, lung cancer risk prediction modelling and prediction modelling of which pulmonary nodules detected on computed tomography screening are cancer. His lung cancer risk prediction models, including the PLCOm2012 (Tammemagi MC et al. NEJM 2013) and his nodule malignancy probability model (PanCan model; McWilliams A, Tammemagi M, et al. NEJM 2013) have received widespread validation and implementation. Regarding programmatic public health implementation of lung cancer screening, he has a strong research and applied interest in indicators and measures of screening performance through the different phases of lung cancer screening programs.


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


Nucleix

Nucleix is a global leader in creating cancer diagnostic panels based on epigenetic biomarkers. Backed by OrbiMed and other leading investors, Nucleix provides a strong pipeline of products for various cancer types.


Industries

Headquarters

Na'an, Israel

Employees

51-200

Links